Company: LENZ
Filing Date: 2025-04-09
Form Type: 424B3
Source: 0001628280-25-017190
Chunk: 0

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-09
Form: 424B3
Chunk 0
---
#### Filed Pursuant to Rule 424(b)(3)

#### Registration No. 333-282036
| PROSPECTUS |

#### 1,578,947 Shares of Common Stock
This prospectus relates to the resale by the selling stockholder named in this prospectus (the “selling stockholder”) of 1,578,947 shares of common stock, par value $0.00001 per share (the “Common Stock”) that were sold and issued to the selling stockholder in a private placement pursuant to a stock purchase agreement, dated July 14, 2024, which closed on July 17, 2024 (the “July 2024 PIPE Financing”). This prospectus also covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions.

We are registering the resale of these securities to satisfy certain registration rights we have granted. We will not receive any of the proceeds from the sale of the securities by the selling stockholder. We will pay the expenses associated with registering the sales by the selling stockholder, as described in more detail in the section titled “ Use of Proceeds ” appearing elsewhere in this prospectus.

The selling stockholder may sell the securities described in this prospectus in a number of different ways and at varying prices. We provide more information about how the selling stockholder may sell its securities in the section titled “ Plan of Distribution ” appearing elsewhere in this prospectus.

The selling stockholder may sell any, all or none of the securities and we do not know when or in what amount the selling stockholder may sell its securities hereunder following the effective date of this registration statement.

Our Common Stock is listed on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “LENZ.” On April 8, 2025, the last quoted sale price for our Common Stock as reported on Nasdaq was $18.32.

We are an “emerging growth company,” as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in the section titled “

#### Risk Factors

#### ” beginning on page

#### 6
of this prospectus and under similar headings in any amendments or supplements to this prospectus and the documents incorporated herein by reference.

You should rely only on the information